LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

The companies will jointly develop and market trastuzumab deruxtecan worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a ... Enhertu, also known as trastuzumab deruxtecan or T-DXd, is a third-generation ADC that is changing the treatment landscape of breast ...

AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...